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OBJECTIVES: Mantle cell lymphoma (MCL) is an aggressive sub-type of non-
 Hodgkin’s lymphoma (NHL) with a poor prognosis. Approximately 6% of incident 
NHL cases are MCL. Following initial treatment, relapsed MCL cases have an 18-
month median survival. In 2008, Health Canada approved bortezomib for relapsed 
MCL patients. Although there is no standard treatment for relapsed MCL, a Canadian 
physician survey indicated FCM (ﬂudarabine, cyclophosphamide, mitoxantrone) was 
a commonly used regimen. Rituximab-containing regimens were excluded as com-
parators because rituximab re-treatment was not uniformly accessible. However, the 
FCM regimen was accessible across Canada. The objective was to evaluate the cost-
effectiveness of bortezomib versus FCM. METHODS: The PINNACLE single-arm 
study evaluated bortezomib in relapsed MCL patients. Most of these patients had 
received rituximab previously, and therefore provided rationale to support using a 
non-rituximab regimen as a comparator. Published literature identiﬁed one relevant 
FCM study. A ﬁve-year time horizon was selected as most patients were at this point 
deceased. Costs and beneﬁts were discounted by 5% and a provincial Ministry of 
Health perspective was taken. The overall survival for bortezomib was projected 
based on the PINNACLE study. Health utilities were obtained from a published study 
on aggressive NHL. Resource use included costs of drugs, intravenous administration 
and managing key adverse events. The survival of relapsed MCL patients treated with 
standard chemotherapy, including ﬂudarabine regimens, was validated from a cohort 
of patients from the British Columbia Cancer Agency. This ensured the FCM data in 
the analysis was not an underestimation of actual practice results. RESULTS: The 
discounted QALYs were 1.47 (Bortezomib) and 0.86 (FCM). The total cost was 
CAN $27,886 (bortezomib) and $5,059 (FCM). The ICER was $37,253 per QALY. 
Results were most sensitive to the amount of bortezomib used and the survival of 
these patients. CONCLUSIONS: Bortezomib is an approved and cost-effective option 
in these difﬁcult to treat patients.
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OBJECTIVES: To estimate the incremental cost-effectiveness of bortezomib (BTZ) 
compared with lenalidomide plus dexamethasone (LENDEX) and dexamethasone 
(DEX) for the treatment of relapsed/refractory multiple myeloma in the Nordic coun-
tries. METHODS: The model was based on a ‘partitioned survival analysis’ that 
allows survival data to be decomposed into three states 1) alive before disease progres-
sion; 2) alive after progression; and 3) dead. The effects of treatment on time to pro-
gression and overall survival (OS) were obtained from published reports of the APEX, 
MM-009 and MM-010 randomized clinical trials. OS hazard ratios were estimated 
using a mixed-treatment-comparison meta analysis. Costs were estimated using pub-
lished local sources and local Delphi panels, and include drug and administration, 
adverse events and relapses, and end-of-life costs. Utility estimates are derived from 
the literature. The robustness was evaluated by 1-way and probabilistic sensitivity 
analysis. RESULTS: BTZ mean OS is 38.6 months compared to 24.5 and 37.8 months 
for DEX and LENDEX respectively. Mean lifetime direct medical costs for BTZ are 
ranging from a98,408 (Sweden) to a194,656 (Denmark). For Finland, Norway and 
Sweden mean incremental cost per LYG of BTZ compared to DEX is between a42,145 
and a46,749. The corresponding cost per QALY is between a54,451 and a60,564. 
Denmark has higher values of a62,748 and a81,560 respectively. BTZ is dominant 
compared to LENDEX in all countries. For the BTZ DEX comparison, the model is 
most sensitive to changes in utilities prior to relapse, BTZ costs and number of 
administrations. CONCLUSIONS: BTZ and LENDEX are projected to prolong 
survival relative to DEX. Finland, Norway and Sweden show very similar cost-
 effectiveness results. Denmark has higher ICERs because of higher cost of care in 2nd 
and 3rd line implying a relative disadvantage for drugs prolonging life. From a Nordic 
perspective, BTZ is cost-effective compared to DEX and dominant compared to 
LENDEX.
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OBJECTIVES: New treatment options for advanced non-squamous NSCLC offer 
improved survival over standard chemotherapy but must also offer value for money. 
Bevacizumab, a humanised monoclonal antibody against VEGF, plus chemotherapy 
increases overall survival and progression-free-survival (PFS) in advanced NSCLC 
patients versus chemotherapy alone. Pemetrexed, a thymidylate synthase inhibitor, has 
shown non-inferiority over cisplatin plus gemcitabine. This study evaluated the cost-
effectiveness of BCG compared with iPC in Germany. METHODS: A Markov model 
evaluated the average costs and beneﬁts of treating advanced or recurrent NSCLC 
patients with BCG or PC. The patient characteristics of an average German hospital 
patient were applied. The model assumes patients move from pre-progressive to pro-
gressed disease to death, according to a set of transition probabilities derived from 
the respective pivotal trials and appropriate indirect comparison methodology. Drug 
costs assume underlying chemotherapy is given for up to 6 cycles, but that bevaci-
zumab is administered until progression or unacceptable toxicity. The model estimates 
average survival, PFS, drug, administration and progression costs per patient treated 
with BCG or PC and the incremental cost-effectiveness ratio. RESULTS: BCG gave 
mean survival of 1.51 versus 1.31 years with PC and mean PFS of 0.75 versus 0.54 
years, respectively. The mean total monthly treatment costs for the base case analysis 
were a5870 versus a6637, respectively (savings of a767 for BCG per patient). Monthly 
drug costs alone were a5497 for BCG compared with a6161 with PC. CONCLU-
SIONS: BCG triplet-therapy offers greater clinical beneﬁts than PC doublet-therapy 
at a lower overall cost, suggesting that BCG is dominating PC in treating patients with 
advanced NSCLC in Germany. The overall cost of BCG is likely to further reduce 
following the recent gemcitabine patent expiry, providing potential further cost 
savings of BCG to the German health care system.
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OBJECTIVES: To evaluate the costs and clinical outcomes of rituximab (R) added to 
ﬁrst line chemotherapy vs. chemotherapy in patients with chronic lymphocytic leuke-
mia (CLL) in Poland. METHODS: A three health state transition model was developed 
to evaluate the cost-effectiveness of treating patients with either chemotherapy 
(ﬂudarabine cyclophosphamide; FC) or R  FC. Patient level data were obtained 
from the pivotal study CLL-8 (Hallek et al., 2008). As chlorambucil (C) is frequently 
used in Poland, an indirect comparison of R-FC vs. C was included (patient data were 
obtained from the CLL-4 study, Catovsky et al. 2007). Patients commenced in the 
progression-free (PFS) state with transitions to progressive disease or death. PFS and 
overall survival (OS) data were extrapolated over 15 years with monthly cycles. Utility 
values originated from Hancock et. al., 2002 study. The perspective was the Public 
Payer. Direct costs were obtained from 4 reference oncology centers and derived from 
the National Health Fund. Effects and costs (PLN) were discounted at 3.5% and 5% 
p.a. respectively (Polish HTA guidelines). RESULTS: R-FC was more effective than 
FC or C. R-FC treatment resulted in 0.92 life years gained (LYG) and 0.79 quality–
adjusted life years (QALY) vs. FC. Total mean costs per patient were higher for R-FC 
vs. FC, however the incremental cost-effectiveness ratios (ICERs) were 70,145 PLN/
LYG and 81,730 PLN/QALY. The LYG and QALY gains for R-FC vs. chlorambucil 
were 1.87 and 1.63 leading to ICERs of 47,007 PLN/LYG and 53,826 PLN/QALY, 
respectively. Results were most sensitive to discounting rates changes and the time 
horizon. Nevertheless, in all scenarios R-FC treatment remained cost-effective. CON-
CLUSIONS: R-FC substantially improves patients outcomes and is an economically 
effective 1st line treatment for CLL patients when compared to FC or chlorambucil.
PCN89
A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS 
OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS 
CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS 
WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER 
(NSCLC) IN SPAIN
de Castro Carpeño J1, Castro Gómez A2, Walzer S3
1Hospital Universitario de La Paz, Madrid, Spain, 2Roche Farma S.A., Madrid, Spain, 3F. 
Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland
OBJECTIVES: New treatment options for advanced NSCLC can offer improved sur-
vival over standard chemotherapy but should also offer value for money. Bevaci-
zumab, a humanised monoclonal antibody (MAb) against VEGF, plus chemotherapy 
increases overall survival and progression-free-survival in patients with advanced 
NSCLC versus chemotherapy alone. Cetuximab, a MAb targeting EGFR, plus chemo-
therapy also improved outcomes in these patients. This study compared the costs and 
outcomes associated with treating patients with BCG or CVC in Spain. METHODS: 
A Markov model was used to compare costs and outcomes associated with treating 
patients with advanced or recurrent NSCLC with BCG or CVC. The model assumes 
patients move from pre-progressive to progressed disease then to death, according to 
a set of transition probabilities derived from an indirect comparison (IC) of the efﬁcacy 
of BCG and CVC in terms of progression-free survival (PFS) using data from the 
respective pivotal trials and appropriate IC methodology. Cost data were derived from 
local sources. Drug costs assumed chemotherapy was given for up to 6 cycles, cetux-
imab was administered at an initial dose of 400 mg/m2 (then 250 mg/m2 weekly) until 
